{"id":583957,"date":"2026-08-14T00:04:47","date_gmt":"2026-08-14T00:04:47","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/583957\/"},"modified":"2026-08-14T00:04:47","modified_gmt":"2026-08-14T00:04:47","slug":"remepy-raises-36-million-to-expand-ai-enabled-drug-pipeline","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/583957\/","title":{"rendered":"Remepy raises $36 million to expand AI-enabled drug pipeline"},"content":{"rendered":"

Remepy said it raised $36 million in Series A funding to expand its pipeline of drug-software combination treatments and support a planned Phase III trial of its lead Parkinson\u2019s disease program.<\/p>\n

The round was led by O.G. Venture Partners and M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany. Existing and new investors also participated, including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group and IT-Farm Corp.<\/p>\n

The company said the new funding brings its total capital raised to $62 million.<\/p>\n

Remepy is developing what it calls Hybrid Drugs, treatments that combine prescription medications with personalized, AI-driven therapeutic apps. The company said the approach is designed to pair pharmacological treatment with adaptive physical, cognitive and behavioral interventions through a standard prescription model.<\/p>\n

\"Michal<\/a>\"Michal<\/p>\n

Michal Tsur and Or Shoval, Remepy\u2019s co-CEOs <\/p>\n

(Photo: Nati Gold)<\/p>\n

The funding will be used to expand Remepy\u2019s pharmaceutical co-development partnerships, advance its pipeline and platform, and fund global Phase III development of Hybridopa, its lead program for Parkinson\u2019s disease. The trial is expected to begin in the fourth quarter of 2026. Hybridopa is still investigational and has not been approved by the U.S. Food and Drug Administration.<\/p>\n

The company said Hybridopa produced encouraging Phase IIa results, showing improvement in both motor and non-motor symptoms in Parkinson\u2019s patients. Remepy said the results were supported by peer-reviewed publications examining the biological mechanisms behind the treatment\u2019s clinical effect.<\/p>\n

Remepy recently announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, to develop Hybrid Drugs across several indications, beginning with rare tumors.<\/p>\n

\"The<\/a>\"The<\/p>\n

The team at Remepy <\/p>\n

(Photo: Nati Gold)<\/p>\n

\u201cWe believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient,\u201d Michal Tsur and Or Shoval, Remepy\u2019s co-CEOs, said in a statement. \u201cOver the past year, we\u2019ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment and partnerships with leading pharmaceutical companies. This financing allows us to advance Phase III of Hybridopa for Parkinson\u2019s disease, and expand the Hybrid Drug model across multiple therapeutic areas.\u201d<\/p>\n

Ziv Kop, managing partner at O.G. Venture Partners Israel, said Remepy is \u201cpioneering a new category of medicine\u201d by combining biotechnology, AI and digital health.<\/p>\n

\u201cWith compelling clinical data, growing regulatory momentum and strong validation from leading pharmaceutical partners, we believe Hybrid Drugs have the potential to transform patient care,\u201d Kop said.<\/p>\n

Dr. Eyal Ben Ami, scientific lead at M Ventures, said the investment reflects the growing role of AI in health care and drug delivery.<\/p>\n

\u201cRemepy\u2019s pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines,\u201d he said. \u201cWe look forward to advancing it across multiple drug classes and disease areas.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Remepy said it raised $36 million in Series A funding to expand its pipeline of drug-software combination treatments…\n","protected":false},"author":2,"featured_media":583958,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[42,43,40,38,41,39],"class_list":["post-583957","post","type-post","status-publish","format-standard","has-post-thumbnail","category-headlines","tag-headlines","tag-news","tag-top-news","tag-top-stories","tag-topnews","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/583957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=583957"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/583957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/583958"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=583957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=583957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=583957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}